Previous Close | 91.40 |
Open | 91.55 |
Bid | 91.80 x 1400 |
Ask | 92.12 x 800 |
Day's Range | 91.50 - 93.02 |
52 Week Range | 70.89 - 95.72 |
Volume | |
Avg. Volume | 10,539,798 |
Market Cap | 233.264B |
Beta (5Y Monthly) | 0.32 |
PE Ratio (TTM) | 13.99 |
EPS (TTM) | 6.58 |
Earnings Date | Oct 27, 2022 |
Forward Dividend & Yield | 2.76 (3.03%) |
Ex-Dividend Date | Sep 14, 2022 |
1y Target Est | 100.68 |
Subscribe to Yahoo Finance Plus to view Fair Value for MRK
The World Health Organization (WHO) has published its first guideline for Ebola virus disease therapeutics, with new recommendations for using two monoclonal antibodies. Following a systematic review and meta-analysis, WHO recommended two monoclonal antibody treatments, Ebanga (Ansuvimab, mAb114) and Inmazeb (REGN-EB3). Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Inmazeb became the first treatment for the ebola virus when it received FDA approval in October 2020. Merck & Co Inc's (NYSE: MRK)
Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.
Build and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks.